NOACs comparable to warfarin when treating AFib patients with valvular heart disease

Non-vitamin K antagonist oral anticoagulants (NOACs) may be a safe alternative to warfarin when treating patients with atrial fibrillation (AFib) and valvular heart disease (VHD), according to new research published in the American Journal of Cardiology.[1]

“NOACs have replaced a large portion of warfarin use given their better efficacy and safety profiles, proved in multiple randomized controlled trials,” wrote lead author Min Soo Cho, MD, a specialist with ASAN Medical Center in Korea, and colleagues. “However, the role of NOACs in managing valvular AFib remains undetermined, particularly in AFib associated with mitral stenosis (MS). Dabigatran etexilate is a NOAC used to treat nonvalvular AFib; evidence on the efficacy and safety of dabigatran in AFib patients with native VHD is lacking.”

The group examined data from 59 valvular AFib patients given dabigatran and 60 valvular AFib patients given warfarin. All patients were enrolled at a single facility from March 2017 to October 2019. The mean patient age was 61.2 years old, 69% of patients were male and the mean CHA2DS2-VASc score was 2.1.

A significant number of patients (87%) were already taking warfarin prior to being enrolled in this analysis. When the study began, any patients already taking warfarin who were randomized to the dabigatran group stopped taking the warfarin.

Overall, the authors wrote, no strokes or deaths were seen in either patient group. The study’s primary endpoint, stroke or silent brain lesion, was seen in 34% of patients in the dabigatran group and 40% of patients in the conventional treatment/warfarin group. Follow-up MRI results confirmed that there was no difference in the number of new silent brain infarct lesions between the two groups. While clinical bleeding events were less likely among dabigatran patients, the difference was not large enough to be viewed as significant.

There was also no difference when comparing the study’s primary endpoint just among patients presenting with MS.

The rate of adverse events, the authors added, was similar between the two groups—with one exception: gastrointestinal symptoms were seen in 15% of dabigatran patients, but not in conventional treatment/warfarin patients.

“Although dabigatran was associated with more gastrointestinal symptoms, most patients (92%) could complete the 1-year course of treatment,” the authors wrote. “Therefore, we believe that dabigatran could be a reasonable alternative to warfarin in patients with VHD and AFib.”

Related Heart Rhythm Content:

3D cardiac modeling solution for VT ablation receives FDA clearance

Regulatory roundup: FDA clears new solutions from Boston Scientific, CathVision, Franklin Mountain Medical

Real-world Watchman patients experiencing fewer complications after LAAO than seen in clinical trials

Reference:

Min Soo Cho, MD; Minsu Kim, MD, Seung-ah Lee, MD; Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation. The American Journal of Cardiology, June 2022.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup